Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Suganami

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Journal of Atherosclerosis and Thrombosis|February 9, 2025
Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group StudyHidenori Arai, Shizuya Yamashita, Eiichi Araki, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 2, 2024
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 studyHidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, et al.
Therapeutic Innovation & Regulatory Science|February 8, 2020
Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in JapanKentaro Sakamaki, Yusuke Morita, Katsuhiro Iba, et al.
Therapeutic Innovation & Regulatory Science|December 10, 2020
Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in JapanKentaro Sakamaki, Seitaro Yoshida, Yusuke Morita, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Current Practice on Multiplicity Adjustment and Sample Size Calculation in Multi-arm Clinical Trials: An Industry Survey in JapanKentaro Sakamaki, Toshifumi Kamiura, Yusuke Morita, et al.
International Journal of Molecular Sciences|February 10, 2019
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal ImpairmentKoutaro Yokote, Shizuya Yamashita, Hidenori Arai, et al.
Journal of Pharmacological Sciences|February 24, 2006
QT PRODACT: inter- and intra-facility variability of the action potential assay using isolated guinea-pig papillary musclesRyuzaburo Yamazaki, Masayuki Yamada, Kazuo Kobayashi, et al.
Journal of Forensic and Legal Medicine|October 1, 2015
Utilization of bone impedance for age estimation in postmortem casesNoboru Ishikawa, Hideki Suganami, Atsushi Nishida, et al.
Journal of Atherosclerosis and Thrombosis|September 4, 2024
Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 StudyShun Ishibashi, Hidenori Arai, Koutaro Yokote, et al.
Journal of Atherosclerosis and Thrombosis|December 18, 2024
Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL StudyRyohei Tanigawa, Atsushi Nakajima, Yuichiro Eguchi, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Journal of Atherosclerosis and Thrombosis|February 9, 2025
Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group StudyHidenori Arai, Shizuya Yamashita, Eiichi Araki, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|March 2, 2024
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 studyHidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, et al.
Therapeutic Innovation & Regulatory Science|February 8, 2020
Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in JapanKentaro Sakamaki, Yusuke Morita, Katsuhiro Iba, et al.
Therapeutic Innovation & Regulatory Science|December 10, 2020
Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in JapanKentaro Sakamaki, Seitaro Yoshida, Yusuke Morita, et al.
Therapeutic Innovation & Regulatory Science|September 21, 2018
Current Practice on Multiplicity Adjustment and Sample Size Calculation in Multi-arm Clinical Trials: An Industry Survey in JapanKentaro Sakamaki, Toshifumi Kamiura, Yusuke Morita, et al.
International Journal of Molecular Sciences|February 10, 2019
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal ImpairmentKoutaro Yokote, Shizuya Yamashita, Hidenori Arai, et al.
Journal of Pharmacological Sciences|February 24, 2006
QT PRODACT: inter- and intra-facility variability of the action potential assay using isolated guinea-pig papillary musclesRyuzaburo Yamazaki, Masayuki Yamada, Kazuo Kobayashi, et al.
Journal of Forensic and Legal Medicine|October 1, 2015
Utilization of bone impedance for age estimation in postmortem casesNoboru Ishikawa, Hideki Suganami, Atsushi Nishida, et al.
Journal of Atherosclerosis and Thrombosis|September 4, 2024
Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 StudyShun Ishibashi, Hidenori Arai, Koutaro Yokote, et al.
Journal of Atherosclerosis and Thrombosis|December 18, 2024
Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL StudyRyohei Tanigawa, Atsushi Nakajima, Yuichiro Eguchi, et al.
Pageof 7